Department of Pharmacology, Xiangya School of Pharmaceutical Sciences, Central South University, Changsha 410078, China.
Zhongguo Dang Dai Er Ke Za Zhi. 2022 Feb 15;24(2):216-222. doi: 10.7499/j.issn.1008-8830.2111005.
Multisystem inflammatory syndrome in children (MIS-C) is a type of hyperinflammatory symptoms similar to Kawasaki disease after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection and is commonly observed in children aged 8-10 years. Primary therapeutic medications for MIS-C are intravenous immunoglobulins and glucocorticoids. It has been reported that biologics, such as IL-1 receptor antagonist anakinra, IL-6 receptor antagonist tocilizumab, and TNF-α receptor antagonist infliximab, can be used as an option for critically ill patients. This article elaborates on the mechanism of action of the above biologics and discusses the efficacy and safety biologics in the treatment of MIS-C after SARS-CoV-2 infection, in order to provide methods for the treatment of MIS-C with severe symptoms.
儿童多系统炎症综合征（MIS-C）是一种类似于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）感染后的川崎病的过度炎症症状，常见于 8-10 岁儿童。MIS-C 的主要治疗药物是静脉注射免疫球蛋白和糖皮质激素。据报道，生物制剂，如白细胞介素 1 受体拮抗剂阿那白滞素、白细胞介素 6 受体拮抗剂托珠单抗和肿瘤坏死因子-α 受体拮抗剂英夫利昔单抗，可作为危重症患者的选择。本文详细阐述了上述生物制剂的作用机制，并讨论了生物制剂在治疗 SARS-CoV-2 感染后 MIS-C 的疗效和安全性，以期为重症 MIS-C 的治疗提供方法。
